@pubmed.ncbi.nlm.nih.gov.rss-feed.feed.id.1za4h3qg-nd.lvx8qfap6dogsjorqfx5gx1cfzpjgvflxsasr2.ff.20240827193420.utm.medium.rss.utm.content.1za4h3qg-nd.lvx8qfap6dogsjorqfx5gx1cfzpjgvflxsasr2.utm.source.rss-parrot-bot.v.2.18.0.post9.e462414@rss-parrot.net
I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline! Brought to you by the RSS Parrot.
---
((Triple Negative Breast Neoplasmspathology[MAJR])): Latest results from PubMed
Feed URL: pubmed.ncbi.nlm.nih.gov/rss/search/1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2/
Posts: 10
Followers: 2
Spatial architecture of tumor-infiltrating lymphocytes adds predictive value beyond stromal TIL density for neoadjuvant response in triple-negative breast cancer
Published: September 19, 2026 10:00
CONCLUSION: In this exploratory single-center retrospective cohort, the H&E-derived SAI provided internally validated predictive information beyond stromal TIL density for pCR. External multicenter validation, assessment of intersite technical…
Pemetrexed increases BRCA1 protein stability and sensitizes TNBC cells to radiotherapy
Published: September 18, 2026 10:00
BRCA1 is a multifunctional tumor suppressor that orchestrates homologous recombination repair, chromatin remodeling, cell cycle control and apoptosis. Although pathogenic BRCA1 mutations are relatively uncommon, decreased BRCA1 protein expression, which is…
A Case of Pembrolizumab-Associated Fulminant Type One Diabetes Mellitus during Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
Published: September 17, 2026 10:00
A woman in her 50s was diagnosed with Stage ⅡA triple-negative breast cancer (TNBC) and neoadjuvant chemotherapy with pembrolizumab, carboplatin, and paclitaxel was initiated. On day 125 of treatment, the patient presented to the emergency department with…
Spatial immune biomarkers in triple-negative breast cancer: emerging evidence, technology trade-offs, and barriers to clinical translation
Published: September 16, 2026 10:00
Triple-negative breast cancer (TNBC) is an immunogenic but clinically heterogeneous breast cancer subtype. Stromal tumor-infiltrating lymphocytes (TILs), PD-L1 expression, and tumor mutational burden provide useful but incomplete summaries of the tumor…
Successful treatment of a large-sized triple-negative breast cancer: A case report
Published: September 15, 2026 10:00
RATIONALE: Triple-negative breast cancer (TNBC) is defined as the absence of estrogen receptor and progesterone receptor expression, along with a lack of human epidermal growth factor receptor 2 overexpression or amplification. Patients with TNBC exhibit a…
Time-Dependent Multimechanistic Antitumor Effects of Olive Oil Phenolics in a Triple-Negative Breast Cancer Mouse Model
Published: September 15, 2026 10:00
Background/Objectives: The health-protective properties of olive oil phenolics, including their potential chemopreventive and anticancer effects, have attracted considerable scientific interest. However, their in vivo efficacy and mechanisms of action…
Long Noncoding RNAs (lncRNAs) as Biomarkers of Prognosis in TNBC and Non-TNBC Breast Cancer Patients
Published: September 15, 2026 10:00
Functional studies have shown that long noncoding RNAs (lncRNAs) play different roles in gene expression regulation, acting as epigenetic factors. Accumulating evidence indicates that lncRNAs modulate diverse biological processes, and their altered…
Integrative Molecular Profiling of miR-548f-3p in Triple-Negative Breast Cancer Highlights ANP32E as a Candidate Downstream Effector
Published: September 15, 2026 10:00
Triple-negative breast cancer (TNBC) remains a major therapeutic challenge due to pronounced molecular heterogeneity, transcriptional plasticity, and frequent treatment resistance. MicroRNA (miRNA)-based strategies have emerged as potential approaches for…
TFAP2B and FOXC1 are associated with biologically and clinically distinct differentiation states in triple-negative breast cancer
Published: September 12, 2026 10:00
Triple-negative breast cancer (TNBC) comprises biologically distinct subtypes, including luminal androgen receptor (LAR) tumors, but routine immunohistochemical markers incompletely capture lineage-associated differentiation states. We investigated TFAP2B,…
Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab
Published: September 11, 2026 10:00
CONCLUSION: The tumor-informed MRD assay demonstrated high baseline ctDNA prevalence, marked clearance with NAT, and strong prognostic utility of post-NAT and postsurgery ctDNA-positive status for distant recurrence in early TNBC.